Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report

This publication has 13 references indexed in Scilit:

• Identification of a novel crizotinib-sensitive MET–ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing
  Annals of Oncology, 2018
• MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma
  Journal of Thoracic Oncology, 2018
• Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib
  Journal of Thoracic Oncology, 2018
• Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients
  Clinical Cancer Research, 2018
• KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma
  Journal of Thoracic Oncology, 2018
• Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion
  JCO Precision Oncology, 2017
• Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
  Cancer Discovery, 2016
• Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
  Nature Medicine, 2016
• Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
  Cancer Discovery, 2015
• Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
  Journal of Thoracic Oncology, 2011